GlycoMimetics Inc Market Cap ($10.13 Million)
Market Cap & Net Worth: GlycoMimetics Inc (GLYC)
GlycoMimetics Inc market cap. GlycoMimetics Inc (NASDAQ:GLYC) has a market capitalization of $10.13 Million ($10.13 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26903 globally and #5596 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GlycoMimetics Inc's stock price $0.16 by its total outstanding shares 64532100 (64.53 Million). Also see GLYC operating cash flow for how efficiently the company converts equity into cash flow.
GlycoMimetics Inc Market Cap History (2015–2025)
GlycoMimetics Inc market cap history from 2015 to 2025. Data shows change from $369.12 Million to $10.13 Million (-32.10% CAGR). Check GlycoMimetics Inc stock quote for real-time trading data and today's change.
Index Memberships
GlycoMimetics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #750 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2455 of 3165 |
Weight: GlycoMimetics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GlycoMimetics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GlycoMimetics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of GlycoMimetics Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
15229.58x
GlycoMimetics Inc's market cap is 15229.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $369.12 Million | $20.07 Million | -$12.77 Million | 18.39x | N/A |
| 2016 | $393.65 Million | $18.00K | -$31.81 Million | 21869.21x | N/A |
| 2019 | $341.37 Million | $9.00 Million | -$54.12 Million | 37.93x | N/A |
| 2020 | $242.64 Million | $10.16 Million | -$50.27 Million | 23.87x | N/A |
| 2021 | $92.93 Million | $1.16 Million | -$63.14 Million | 80.11x | N/A |
| 2022 | $195.53 Million | $74.92K | -$93.33 Million | 2609.71x | N/A |
| 2023 | $152.30 Million | $10.00K | -$36.90 Million | 15229.58x | N/A |
Competitor Companies of GLYC by Market Capitalization
Companies near GlycoMimetics Inc in the global market cap rankings as of November 5, 2026. Also see GlycoMimetics Inc (GLYC) total assets for a full breakdown of the balance sheet.
Key companies related to GlycoMimetics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of GlycoMimetics Inc (2015–2025)
Market capitalization of GlycoMimetics Inc from 2015 to today. Between 2015 and today, GlycoMimetics Inc's market cap moved from $369.12 Million to $ 10.13 Million, with a yearly change of -32.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $10.13 Million | -36.95% |
| 2024 | $16.07 Million | -89.45% |
| 2023 | $152.30 Million | -22.11% |
| 2022 | $195.53 Million | +110.42% |
| 2021 | $92.93 Million | -61.70% |
| 2020 | $242.64 Million | -28.92% |
| 2019 | $341.37 Million | -44.14% |
| 2018 | $611.12 Million | -43.60% |
| 2017 | $1.08 Billion | +175.25% |
| 2016 | $393.65 Million | +6.64% |
| 2015 | $369.12 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 12th, 2026 the market cap of GlycoMimetics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.13 Million USD |
| MoneyControl | $10.13 Million USD |
| MarketWatch | $10.13 Million USD |
| marketcap.company | $10.13 Million USD |
| Reuters | $10.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GlycoMimetics Inc
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.